openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS Studies on the teratogenicity of pyrazole compounds in animals have yielded inconclusive results. Up to the present time, however, there have been no reported cases of human congenital malformation proved to be due to the use of the drug. It is suggested that Anturane be used with caution in pregnant women, weighing the potential risks against the possible benefits.
ADVERSE REACTIONS The most frequently reported adverse reactions with Anturane have been upper gastrointestinal disturbances. In these patients it is advisable to administer the drug with food, milk, or antacids. Despite this precaution, Anturane may aggravate or reactivate peptic ulcer. Rash has been reported. In most instances, this reaction did not necessitate discontinuance of therapy. In general, Anturane has not been observed to affect electrolyte balance. Blood dyscrasias (anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia) have rarely been reported. There has also been a published report associating Anturane, administered concomitantly with other drugs including colchicine, with leukemia following long-term treatment of patients with gout. However, the circumstances involved in the two cases reported are such that a cause-and-effect relationship to Anturane has not been clearly established.